To address the identified practice gap, we created an on-line CME program.  We evaluated the effectiveness of this online educational intervention to improve knowledge, competence, and confidence among neurologists regarding non-oral acute pharmacotherapies for the management of migraine.

The online continuing medical education (CME) activity format consisted of a 30-minute video discussion between three expert headache specialists. ºÃÉ«ÏÈÉúal effect was assessed by comparing neurologist responses to four identical questions presented before and directly after the intervention.  Appropriate test statistics for the pre- post-design were used. Cohen’s d was used to calculate the effect size of the online education. Data from the participants were collected between March 23, 2022 and May 4, 2022.

Participation in the CME intervention resulted in a moderate educational effect size among neurologists (n=94; d=.51; p<0.001). The following areas showed significant (P <.05) pre- vs post-educational improvements: interpretation of scoring from the Migraine Disability Assessment tool, role of gastroparesis in reducing the efficacy of oral acute migraine therapies, and the selection of an appropriate non-oral acute migraine therapy.  After participating in the activity, 57% of neurologists reported an increase in their confidence in personalizing the selection of non-oral acute therapies for patients with migraine.

The results indicated that the CME-certified 30-minute video discussion between physician experts was effective at improving awareness among neurologists and PCPs regarding the use of non-oral acute migraine therapies. Future educational efforts should continue address the importance of route of administration as a factor in the personalization of treatment for patients with migraine.